StockGuru Shines its Spotlight on Medical Billing Assistance, Inc. (OTCBB: MDBL) As It Commits $2.5 Million Capital Investment into Medical Practice — October 28, 2011

StockGuru Shines its Spotlight on Medical Billing Assistance, Inc. (OTCBB: MDBL) As It Commits $2.5 Million Capital Investment into Medical Practice — October 28, 2011

(Dallas, TX. – October 28, 2011) StockGuru Shines its Spotlight on Medical Billing Assistance, Inc. (OTCBB: MDBL) through one of its wholly owned subsidiaries, FCID Medical, Inc. (FCID). Taking full advantage of positioning itself as a national leader in providing an innovative state-of-the-art approach to healthcare management, the Company announced yesterday the capital infusion of $2.5 million into First Choice Medical Group of Brevard, LLC (“FCMG”).  The Company closed at $0.80 on October 27, 2011, trading in a fifty-two week range of $1.30 – 0.42.

“While MDBL is poised to purchase FCMG, in order to modernize the practice the amount of capital infusion supporting MDBL’s vision of creating a unique business and financial model is further solidified,” says Kris Jones, Vice President of Medical Operations.

In the final stages of due diligence, this capital infusion allows FCMG to parallel MDBL’s vision of becoming a modern state of the art facility, setting a new standard for healthcare going forward. The implementation of a fully functional and robust practice, combining practice management tools, electronic records, billing software and ancillary modalities including MRI, CT, X-Ray and EMG, allows FCMG to be positioned as MDBL’s corporate model.

In today’s volatile healthcare environment, the healthcare market remains a 100 billion dollar industry.  MDBL remains committed to implementing its cost effective, unique business and financial model allowing MDBL’s shareholders to reap the benefits by pinpointing today’s necessities within acquired medical practices to re-create and re-innovate specialty groups to further position the success of the medical practices’ business operations.

MDBL’s commitment to success is driven by top management’s focus and dedication to the company’s unique business and financial model.  “Capital infusions like this one are important to us as we continue to make ourselves the national leader in providing state-of-the-art healthcare management and facilities,” noted MDBL’s CEO, Chris Romandetti.  “The monetary investment into FCMG is the first part of a necessary infrastructure required to prepare the company for the next steps in implementing MDBL’s unique business model,” Romandetti continued.


MDBL has focused its business plan on creating and incorporating state-of-the art technologies and efficiencies into inefficient medical practices by implementing MDBL’s unique business and financial model. MDBL’s newly focused plan, allows physician’s to practice medicine while MDBL takes care of the business.  By acquiring medical practices, MDBL brings in expertise that allows the one-time inefficient medical practice, to become an efficient and streamlined medical practice, while many physicians’ are suffering in today’s healthcare environment, MDBL’s unique model allows physicians to benefit from ancillary services income they currently may not be entitled to. By doing so, MDBL creates a successful structure, reducing stress on the physician, while providing a more conducive environment towards a patient-centric orientation.


FCMG is a multi-specialty medical group located in Melbourne, Florida.  Current specialties and focus within the group are Orthopedic, both operative and non-operative, Sports Medicine, Pain Management and Neurology.


This press release contains statements which address such key issues as MDBL’s growth strategy, future financial results, market positions, product development, medical services and products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of technology development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.

For More Information:


To view this StockGuru Spotlight, please visit:

To get free alerts on this and other similar stocks, please register here:

What is the StockGuru Spotlight?

Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.

StockGuru looks for potential break-out candidates in The StockGuru Spotlight.  Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage.  There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below.   StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.

To feature a company in The StockGuru Spotlight please contact the Publisher at  If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact the StockGuru Publisher John Pentony at this email address: (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions.  SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage.  When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present.  Additionally SG also discloses any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

John Pentony, Publisher,

Tel: +1 469 252 3031